nodes	percent_of_prediction	percent_of_DWPC	metapath
Valsartan—SLCO1B3—Mycophenolate mofetil—systemic scleroderma	0.198	0.278	CbGbCtD
Valsartan—SLCO1B1—Mycophenolate mofetil—systemic scleroderma	0.115	0.162	CbGbCtD
Valsartan—ALB—Captopril—systemic scleroderma	0.0801	0.112	CbGbCtD
Valsartan—SLCO1B3—Methotrexate—systemic scleroderma	0.0793	0.111	CbGbCtD
Valsartan—ALB—Mycophenolate mofetil—systemic scleroderma	0.0631	0.0885	CbGbCtD
Valsartan—CYP2C9—Leflunomide—systemic scleroderma	0.055	0.0772	CbGbCtD
Valsartan—ALB—Prednisone—systemic scleroderma	0.0504	0.0708	CbGbCtD
Valsartan—SLCO1B1—Methotrexate—systemic scleroderma	0.0462	0.0648	CbGbCtD
Valsartan—ALB—Methotrexate—systemic scleroderma	0.0253	0.0355	CbGbCtD
Valsartan—CYP2C9—cardial valve—systemic scleroderma	0.0179	0.405	CbGeAlD
Valsartan—AGTR1—artery—systemic scleroderma	0.00557	0.126	CbGeAlD
Valsartan—AGTR1—endothelium—systemic scleroderma	0.00471	0.107	CbGeAlD
Valsartan—AGTR1—blood vessel—systemic scleroderma	0.00434	0.0983	CbGeAlD
Valsartan—AGTR1—connective tissue—systemic scleroderma	0.00222	0.0504	CbGeAlD
Valsartan—SLCO1B3—lung—systemic scleroderma	0.00221	0.0501	CbGeAlD
Valsartan—AGTR1—smooth muscle tissue—systemic scleroderma	0.00204	0.0461	CbGeAlD
Valsartan—SLCO1B1—digestive system—systemic scleroderma	0.00153	0.0347	CbGeAlD
Valsartan—AGTR1—tendon—systemic scleroderma	0.00153	0.0346	CbGeAlD
Valsartan—AGTR1—lung—systemic scleroderma	0.00134	0.0304	CbGeAlD
Valsartan—CYP2C9—digestive system—systemic scleroderma	0.000774	0.0175	CbGeAlD
Valsartan—Losartan—ACE—systemic scleroderma	0.000738	1	CrCbGaD
Valsartan—Chest pain—Lisinopril—systemic scleroderma	0.000288	0.00119	CcSEcCtD
Valsartan—Anxiety—Lisinopril—systemic scleroderma	0.000287	0.00118	CcSEcCtD
Valsartan—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000287	0.00118	CcSEcCtD
Valsartan—Dyspnoea—Leflunomide—systemic scleroderma	0.000287	0.00118	CcSEcCtD
Valsartan—Hypotension—Mycophenolic acid—systemic scleroderma	0.000287	0.00118	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000286	0.00118	CcSEcCtD
Valsartan—Muscle spasms—Mycophenolate mofetil—systemic scleroderma	0.000285	0.00118	CcSEcCtD
Valsartan—Dyspepsia—Leflunomide—systemic scleroderma	0.000283	0.00117	CcSEcCtD
Valsartan—Vomiting—Mometasone—systemic scleroderma	0.000283	0.00116	CcSEcCtD
Valsartan—Dry mouth—Lisinopril—systemic scleroderma	0.000282	0.00116	CcSEcCtD
Valsartan—Rash—Mometasone—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Valsartan—Asthenia—Captopril—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Valsartan—Dermatitis—Mometasone—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Valsartan—Decreased appetite—Leflunomide—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00028	0.00115	CcSEcCtD
Valsartan—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000279	0.00115	CcSEcCtD
Valsartan—Headache—Mometasone—systemic scleroderma	0.000278	0.00115	CcSEcCtD
Valsartan—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000278	0.00114	CcSEcCtD
Valsartan—Insomnia—Mycophenolic acid—systemic scleroderma	0.000278	0.00114	CcSEcCtD
Valsartan—Fatigue—Leflunomide—systemic scleroderma	0.000277	0.00114	CcSEcCtD
Valsartan—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000276	0.00114	CcSEcCtD
Valsartan—Oedema—Lisinopril—systemic scleroderma	0.000276	0.00114	CcSEcCtD
Valsartan—Pruritus—Captopril—systemic scleroderma	0.000276	0.00114	CcSEcCtD
Valsartan—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.000276	0.00114	CcSEcCtD
Valsartan—Constipation—Leflunomide—systemic scleroderma	0.000275	0.00113	CcSEcCtD
Valsartan—Infection—Lisinopril—systemic scleroderma	0.000275	0.00113	CcSEcCtD
Valsartan—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000274	0.00113	CcSEcCtD
Valsartan—Somnolence—Mycophenolic acid—systemic scleroderma	0.000273	0.00112	CcSEcCtD
Valsartan—Shock—Lisinopril—systemic scleroderma	0.000272	0.00112	CcSEcCtD
Valsartan—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000271	0.00112	CcSEcCtD
Valsartan—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000271	0.00112	CcSEcCtD
Valsartan—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00027	0.00111	CcSEcCtD
Valsartan—Neutropenia—Prednisone—systemic scleroderma	0.00027	0.00111	CcSEcCtD
Valsartan—Abdominal pain—Azathioprine—systemic scleroderma	0.000269	0.00111	CcSEcCtD
Valsartan—Skin disorder—Lisinopril—systemic scleroderma	0.000269	0.00111	CcSEcCtD
Valsartan—Diarrhoea—Captopril—systemic scleroderma	0.000267	0.0011	CcSEcCtD
Valsartan—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000267	0.0011	CcSEcCtD
Valsartan—Vertigo—Mycophenolate mofetil—systemic scleroderma	0.000267	0.0011	CcSEcCtD
Valsartan—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000266	0.0011	CcSEcCtD
Valsartan—Erectile dysfunction—Prednisone—systemic scleroderma	0.000266	0.0011	CcSEcCtD
Valsartan—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000265	0.00109	CcSEcCtD
Valsartan—Fatigue—Mycophenolic acid—systemic scleroderma	0.000265	0.00109	CcSEcCtD
Valsartan—Nausea—Mometasone—systemic scleroderma	0.000264	0.00109	CcSEcCtD
Valsartan—Anorexia—Lisinopril—systemic scleroderma	0.000264	0.00109	CcSEcCtD
Valsartan—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000263	0.00108	CcSEcCtD
Valsartan—Constipation—Mycophenolic acid—systemic scleroderma	0.000262	0.00108	CcSEcCtD
Valsartan—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000262	0.00108	CcSEcCtD
Valsartan—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000261	0.00107	CcSEcCtD
Valsartan—Cough—Mycophenolate mofetil—systemic scleroderma	0.000259	0.00107	CcSEcCtD
Valsartan—Hypotension—Lisinopril—systemic scleroderma	0.000258	0.00106	CcSEcCtD
Valsartan—Dizziness—Captopril—systemic scleroderma	0.000258	0.00106	CcSEcCtD
Valsartan—Urticaria—Leflunomide—systemic scleroderma	0.000256	0.00105	CcSEcCtD
Valsartan—Abdominal pain—Leflunomide—systemic scleroderma	0.000254	0.00105	CcSEcCtD
Valsartan—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00104	CcSEcCtD
Valsartan—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00104	CcSEcCtD
Valsartan—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000253	0.00104	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000252	0.00104	CcSEcCtD
Valsartan—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000252	0.00104	CcSEcCtD
Valsartan—Hypersensitivity—Azathioprine—systemic scleroderma	0.000251	0.00103	CcSEcCtD
Valsartan—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000251	0.00103	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000251	0.00103	CcSEcCtD
Valsartan—Insomnia—Lisinopril—systemic scleroderma	0.00025	0.00103	CcSEcCtD
Valsartan—Paraesthesia—Lisinopril—systemic scleroderma	0.000248	0.00102	CcSEcCtD
Valsartan—Vomiting—Captopril—systemic scleroderma	0.000248	0.00102	CcSEcCtD
Valsartan—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000247	0.00102	CcSEcCtD
Valsartan—Dyspnoea—Lisinopril—systemic scleroderma	0.000246	0.00102	CcSEcCtD
Valsartan—Rash—Captopril—systemic scleroderma	0.000246	0.00101	CcSEcCtD
Valsartan—Dermatitis—Captopril—systemic scleroderma	0.000246	0.00101	CcSEcCtD
Valsartan—Somnolence—Lisinopril—systemic scleroderma	0.000246	0.00101	CcSEcCtD
Valsartan—Headache—Captopril—systemic scleroderma	0.000245	0.00101	CcSEcCtD
Valsartan—Dyspepsia—Lisinopril—systemic scleroderma	0.000243	0.001	CcSEcCtD
Valsartan—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000243	0.001	CcSEcCtD
Valsartan—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000998	CcSEcCtD
Valsartan—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000242	0.000998	CcSEcCtD
Valsartan—Infection—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000991	CcSEcCtD
Valsartan—Decreased appetite—Lisinopril—systemic scleroderma	0.00024	0.00099	CcSEcCtD
Valsartan—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000239	0.000983	CcSEcCtD
Valsartan—Fatigue—Lisinopril—systemic scleroderma	0.000238	0.000982	CcSEcCtD
Valsartan—Shock—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000982	CcSEcCtD
Valsartan—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000238	0.000979	CcSEcCtD
Valsartan—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000237	0.000977	CcSEcCtD
Valsartan—Hypersensitivity—Leflunomide—systemic scleroderma	0.000237	0.000977	CcSEcCtD
Valsartan—Constipation—Lisinopril—systemic scleroderma	0.000236	0.000974	CcSEcCtD
Valsartan—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000969	CcSEcCtD
Valsartan—Diarrhoea—Azathioprine—systemic scleroderma	0.000233	0.00096	CcSEcCtD
Valsartan—Haemoglobin—Prednisone—systemic scleroderma	0.000232	0.000957	CcSEcCtD
Valsartan—Nausea—Captopril—systemic scleroderma	0.000232	0.000955	CcSEcCtD
Valsartan—Haemorrhage—Prednisone—systemic scleroderma	0.000231	0.000952	CcSEcCtD
Valsartan—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000231	0.000951	CcSEcCtD
Valsartan—Asthenia—Leflunomide—systemic scleroderma	0.000231	0.000951	CcSEcCtD
Valsartan—Pruritus—Leflunomide—systemic scleroderma	0.000228	0.000938	CcSEcCtD
Valsartan—Connective tissue disorder—Prednisone—systemic scleroderma	0.000227	0.000936	CcSEcCtD
Valsartan—Hypotension—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000932	CcSEcCtD
Valsartan—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000226	0.000931	CcSEcCtD
Valsartan—Neutropenia—Methotrexate—systemic scleroderma	0.000226	0.00093	CcSEcCtD
Valsartan—Dizziness—Azathioprine—systemic scleroderma	0.000225	0.000928	CcSEcCtD
Valsartan—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000224	0.000924	CcSEcCtD
Valsartan—Erectile dysfunction—Methotrexate—systemic scleroderma	0.000222	0.000916	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000221	0.000909	CcSEcCtD
Valsartan—Photosensitivity reaction—Methotrexate—systemic scleroderma	0.00022	0.000907	CcSEcCtD
Valsartan—Asthenia—Mycophenolic acid—systemic scleroderma	0.00022	0.000907	CcSEcCtD
Valsartan—Diarrhoea—Leflunomide—systemic scleroderma	0.00022	0.000907	CcSEcCtD
Valsartan—Urticaria—Lisinopril—systemic scleroderma	0.00022	0.000905	CcSEcCtD
Valsartan—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000219	0.000903	CcSEcCtD
Valsartan—Abdominal pain—Lisinopril—systemic scleroderma	0.000219	0.0009	CcSEcCtD
Valsartan—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000218	0.000896	CcSEcCtD
Valsartan—Pruritus—Mycophenolic acid—systemic scleroderma	0.000217	0.000895	CcSEcCtD
Valsartan—Vomiting—Azathioprine—systemic scleroderma	0.000217	0.000892	CcSEcCtD
Valsartan—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000216	0.00089	CcSEcCtD
Valsartan—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000215	0.000887	CcSEcCtD
Valsartan—Infestation—Methotrexate—systemic scleroderma	0.000215	0.000886	CcSEcCtD
Valsartan—Infestation NOS—Methotrexate—systemic scleroderma	0.000215	0.000886	CcSEcCtD
Valsartan—Rash—Azathioprine—systemic scleroderma	0.000215	0.000885	CcSEcCtD
Valsartan—Dermatitis—Azathioprine—systemic scleroderma	0.000215	0.000884	CcSEcCtD
Valsartan—Headache—Azathioprine—systemic scleroderma	0.000213	0.000879	CcSEcCtD
Valsartan—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.000213	0.000878	CcSEcCtD
Valsartan—Dizziness—Leflunomide—systemic scleroderma	0.000213	0.000876	CcSEcCtD
Valsartan—Renal failure—Methotrexate—systemic scleroderma	0.000212	0.000871	CcSEcCtD
Valsartan—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000211	0.000867	CcSEcCtD
Valsartan—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00021	0.000865	CcSEcCtD
Valsartan—Angiopathy—Prednisone—systemic scleroderma	0.00021	0.000864	CcSEcCtD
Valsartan—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000209	0.000861	CcSEcCtD
Valsartan—Immune system disorder—Prednisone—systemic scleroderma	0.000209	0.00086	CcSEcCtD
Valsartan—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000207	0.000853	CcSEcCtD
Valsartan—Vomiting—Leflunomide—systemic scleroderma	0.000205	0.000843	CcSEcCtD
Valsartan—Alopecia—Prednisone—systemic scleroderma	0.000204	0.000841	CcSEcCtD
Valsartan—Hypersensitivity—Lisinopril—systemic scleroderma	0.000204	0.000839	CcSEcCtD
Valsartan—Dizziness—Mycophenolic acid—systemic scleroderma	0.000203	0.000836	CcSEcCtD
Valsartan—Epistaxis—Methotrexate—systemic scleroderma	0.000203	0.000836	CcSEcCtD
Valsartan—Rash—Leflunomide—systemic scleroderma	0.000203	0.000836	CcSEcCtD
Valsartan—Dermatitis—Leflunomide—systemic scleroderma	0.000203	0.000835	CcSEcCtD
Valsartan—Mental disorder—Prednisone—systemic scleroderma	0.000202	0.000834	CcSEcCtD
Valsartan—Nausea—Azathioprine—systemic scleroderma	0.000202	0.000834	CcSEcCtD
Valsartan—Headache—Leflunomide—systemic scleroderma	0.000202	0.00083	CcSEcCtD
Valsartan—Malnutrition—Prednisone—systemic scleroderma	0.000201	0.000829	CcSEcCtD
Valsartan—Asthenia—Lisinopril—systemic scleroderma	0.000198	0.000817	CcSEcCtD
Valsartan—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000816	CcSEcCtD
Valsartan—Pruritus—Lisinopril—systemic scleroderma	0.000196	0.000806	CcSEcCtD
Valsartan—Vomiting—Mycophenolic acid—systemic scleroderma	0.000195	0.000804	CcSEcCtD
Valsartan—Haemoglobin—Methotrexate—systemic scleroderma	0.000194	0.0008	CcSEcCtD
Valsartan—Rash—Mycophenolic acid—systemic scleroderma	0.000194	0.000797	CcSEcCtD
Valsartan—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000193	0.000797	CcSEcCtD
Valsartan—Haemorrhage—Methotrexate—systemic scleroderma	0.000193	0.000796	CcSEcCtD
Valsartan—Hepatitis—Methotrexate—systemic scleroderma	0.000193	0.000796	CcSEcCtD
Valsartan—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000192	0.000793	CcSEcCtD
Valsartan—Headache—Mycophenolic acid—systemic scleroderma	0.000192	0.000792	CcSEcCtD
Valsartan—Pharyngitis—Methotrexate—systemic scleroderma	0.000192	0.00079	CcSEcCtD
Valsartan—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000789	CcSEcCtD
Valsartan—Nausea—Leflunomide—systemic scleroderma	0.000191	0.000787	CcSEcCtD
Valsartan—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000191	0.000786	CcSEcCtD
Valsartan—Vision blurred—Prednisone—systemic scleroderma	0.00019	0.000781	CcSEcCtD
Valsartan—Urethral disorder—Methotrexate—systemic scleroderma	0.000189	0.00078	CcSEcCtD
Valsartan—Diarrhoea—Lisinopril—systemic scleroderma	0.000189	0.000779	CcSEcCtD
Valsartan—Angioedema—Prednisone—systemic scleroderma	0.000184	0.000757	CcSEcCtD
Valsartan—Dizziness—Lisinopril—systemic scleroderma	0.000183	0.000753	CcSEcCtD
Valsartan—Nausea—Mycophenolic acid—systemic scleroderma	0.000182	0.000751	CcSEcCtD
Valsartan—Vertigo—Prednisone—systemic scleroderma	0.000181	0.000745	CcSEcCtD
Valsartan—Syncope—Prednisone—systemic scleroderma	0.00018	0.000743	CcSEcCtD
Valsartan—Cardiac disorder—Methotrexate—systemic scleroderma	0.000179	0.000738	CcSEcCtD
Valsartan—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000735	CcSEcCtD
Valsartan—Loss of consciousness—Prednisone—systemic scleroderma	0.000177	0.000728	CcSEcCtD
Valsartan—Vomiting—Lisinopril—systemic scleroderma	0.000176	0.000724	CcSEcCtD
Valsartan—Angiopathy—Methotrexate—systemic scleroderma	0.000175	0.000722	CcSEcCtD
Valsartan—Immune system disorder—Methotrexate—systemic scleroderma	0.000174	0.000719	CcSEcCtD
Valsartan—Rash—Lisinopril—systemic scleroderma	0.000174	0.000718	CcSEcCtD
Valsartan—Dermatitis—Lisinopril—systemic scleroderma	0.000174	0.000717	CcSEcCtD
Valsartan—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000174	0.000717	CcSEcCtD
Valsartan—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000174	0.000716	CcSEcCtD
Valsartan—Headache—Lisinopril—systemic scleroderma	0.000173	0.000713	CcSEcCtD
Valsartan—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000171	0.000706	CcSEcCtD
Valsartan—Arthralgia—Prednisone—systemic scleroderma	0.000171	0.000706	CcSEcCtD
Valsartan—Myalgia—Prednisone—systemic scleroderma	0.000171	0.000706	CcSEcCtD
Valsartan—Anxiety—Prednisone—systemic scleroderma	0.000171	0.000703	CcSEcCtD
Valsartan—Alopecia—Methotrexate—systemic scleroderma	0.000171	0.000703	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.00017	0.000701	CcSEcCtD
Valsartan—Mental disorder—Methotrexate—systemic scleroderma	0.000169	0.000697	CcSEcCtD
Valsartan—Malnutrition—Methotrexate—systemic scleroderma	0.000168	0.000693	CcSEcCtD
Valsartan—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000683	CcSEcCtD
Valsartan—Dysgeusia—Methotrexate—systemic scleroderma	0.000165	0.000678	CcSEcCtD
Valsartan—Nausea—Lisinopril—systemic scleroderma	0.000164	0.000676	CcSEcCtD
Valsartan—Oedema—Prednisone—systemic scleroderma	0.000164	0.000676	CcSEcCtD
Valsartan—Anaphylactic shock—Prednisone—systemic scleroderma	0.000164	0.000676	CcSEcCtD
Valsartan—Infection—Prednisone—systemic scleroderma	0.000163	0.000672	CcSEcCtD
Valsartan—Back pain—Methotrexate—systemic scleroderma	0.000163	0.00067	CcSEcCtD
Valsartan—Shock—Prednisone—systemic scleroderma	0.000162	0.000665	CcSEcCtD
Valsartan—Nervous system disorder—Prednisone—systemic scleroderma	0.000161	0.000663	CcSEcCtD
Valsartan—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.00016	0.00066	CcSEcCtD
Valsartan—Skin disorder—Prednisone—systemic scleroderma	0.000159	0.000657	CcSEcCtD
Valsartan—Vision blurred—Methotrexate—systemic scleroderma	0.000158	0.000653	CcSEcCtD
Valsartan—Anorexia—Prednisone—systemic scleroderma	0.000157	0.000645	CcSEcCtD
Valsartan—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000154	0.000634	CcSEcCtD
Valsartan—Rash—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000629	CcSEcCtD
Valsartan—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000153	0.000629	CcSEcCtD
Valsartan—Headache—Mycophenolate mofetil—systemic scleroderma	0.000152	0.000625	CcSEcCtD
Valsartan—Vertigo—Methotrexate—systemic scleroderma	0.000151	0.000622	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.00015	0.000616	CcSEcCtD
Valsartan—Insomnia—Prednisone—systemic scleroderma	0.000149	0.000612	CcSEcCtD
Valsartan—Paraesthesia—Prednisone—systemic scleroderma	0.000147	0.000607	CcSEcCtD
Valsartan—Cough—Methotrexate—systemic scleroderma	0.000147	0.000604	CcSEcCtD
Valsartan—Dyspepsia—Prednisone—systemic scleroderma	0.000145	0.000595	CcSEcCtD
Valsartan—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000144	0.000593	CcSEcCtD
Valsartan—Arthralgia—Methotrexate—systemic scleroderma	0.000143	0.00059	CcSEcCtD
Valsartan—Chest pain—Methotrexate—systemic scleroderma	0.000143	0.00059	CcSEcCtD
Valsartan—Myalgia—Methotrexate—systemic scleroderma	0.000143	0.00059	CcSEcCtD
Valsartan—Decreased appetite—Prednisone—systemic scleroderma	0.000143	0.000588	CcSEcCtD
Valsartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000142	0.000586	CcSEcCtD
Valsartan—Fatigue—Prednisone—systemic scleroderma	0.000142	0.000583	CcSEcCtD
Valsartan—Constipation—Prednisone—systemic scleroderma	0.00014	0.000578	CcSEcCtD
Valsartan—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000137	0.000565	CcSEcCtD
Valsartan—Infection—Methotrexate—systemic scleroderma	0.000136	0.000562	CcSEcCtD
Valsartan—Nervous system disorder—Methotrexate—systemic scleroderma	0.000135	0.000554	CcSEcCtD
Valsartan—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000134	0.000553	CcSEcCtD
Valsartan—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000134	0.000553	CcSEcCtD
Valsartan—Skin disorder—Methotrexate—systemic scleroderma	0.000133	0.000549	CcSEcCtD
Valsartan—Anorexia—Methotrexate—systemic scleroderma	0.000131	0.000539	CcSEcCtD
Valsartan—Urticaria—Prednisone—systemic scleroderma	0.00013	0.000537	CcSEcCtD
Valsartan—Abdominal pain—Prednisone—systemic scleroderma	0.00013	0.000535	CcSEcCtD
Valsartan—Hypotension—Methotrexate—systemic scleroderma	0.000128	0.000528	CcSEcCtD
Valsartan—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000125	0.000515	CcSEcCtD
Valsartan—Insomnia—Methotrexate—systemic scleroderma	0.000124	0.000511	CcSEcCtD
Valsartan—Paraesthesia—Methotrexate—systemic scleroderma	0.000123	0.000508	CcSEcCtD
Valsartan—Dyspnoea—Methotrexate—systemic scleroderma	0.000122	0.000504	CcSEcCtD
Valsartan—Somnolence—Methotrexate—systemic scleroderma	0.000122	0.000503	CcSEcCtD
Valsartan—Hypersensitivity—Prednisone—systemic scleroderma	0.000121	0.000498	CcSEcCtD
Valsartan—Dyspepsia—Methotrexate—systemic scleroderma	0.000121	0.000498	CcSEcCtD
Valsartan—Decreased appetite—Methotrexate—systemic scleroderma	0.000119	0.000491	CcSEcCtD
Valsartan—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000118	0.000488	CcSEcCtD
Valsartan—Fatigue—Methotrexate—systemic scleroderma	0.000118	0.000487	CcSEcCtD
Valsartan—Asthenia—Prednisone—systemic scleroderma	0.000118	0.000485	CcSEcCtD
Valsartan—Pruritus—Prednisone—systemic scleroderma	0.000116	0.000479	CcSEcCtD
Valsartan—Diarrhoea—Prednisone—systemic scleroderma	0.000112	0.000463	CcSEcCtD
Valsartan—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000112	0.000462	CcSEcCtD
Valsartan—Urticaria—Methotrexate—systemic scleroderma	0.000109	0.000449	CcSEcCtD
Valsartan—Dizziness—Prednisone—systemic scleroderma	0.000109	0.000447	CcSEcCtD
Valsartan—Abdominal pain—Methotrexate—systemic scleroderma	0.000108	0.000447	CcSEcCtD
Valsartan—Vomiting—Prednisone—systemic scleroderma	0.000104	0.00043	CcSEcCtD
Valsartan—Rash—Prednisone—systemic scleroderma	0.000104	0.000426	CcSEcCtD
Valsartan—Dermatitis—Prednisone—systemic scleroderma	0.000103	0.000426	CcSEcCtD
Valsartan—Headache—Prednisone—systemic scleroderma	0.000103	0.000424	CcSEcCtD
Valsartan—Hypersensitivity—Methotrexate—systemic scleroderma	0.000101	0.000416	CcSEcCtD
Valsartan—Asthenia—Methotrexate—systemic scleroderma	9.85e-05	0.000406	CcSEcCtD
Valsartan—Nausea—Prednisone—systemic scleroderma	9.75e-05	0.000402	CcSEcCtD
Valsartan—Pruritus—Methotrexate—systemic scleroderma	9.71e-05	0.0004	CcSEcCtD
Valsartan—Diarrhoea—Methotrexate—systemic scleroderma	9.39e-05	0.000387	CcSEcCtD
Valsartan—Dizziness—Methotrexate—systemic scleroderma	9.07e-05	0.000374	CcSEcCtD
Valsartan—Vomiting—Methotrexate—systemic scleroderma	8.73e-05	0.000359	CcSEcCtD
Valsartan—Rash—Methotrexate—systemic scleroderma	8.65e-05	0.000356	CcSEcCtD
Valsartan—Dermatitis—Methotrexate—systemic scleroderma	8.64e-05	0.000356	CcSEcCtD
Valsartan—Headache—Methotrexate—systemic scleroderma	8.6e-05	0.000354	CcSEcCtD
Valsartan—Nausea—Methotrexate—systemic scleroderma	8.15e-05	0.000336	CcSEcCtD
